Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clarithromycin

FDA-approved product (tablet, oral), marketed as Biaxin, Biaxin Xl, Clarithromycin.

Registered studies
50+
Lab records
25
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Clarithromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Duodenal ulcer
  • Infection
  • Maxillary sinusitis
  • Otitis media
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Macrolides
FDA pharmacologic class
Macrolide Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FA09

Repurposing investigation

Clarithromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae75.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis75.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 10 of 12 lab records
  • E. coli: measured active in 2 of 4 lab records
  • K. pneumoniae: measured active in 7 of 7 lab records
  • M. tuberculosis: measured active in 1 of 2 lab records
Open Clarithromycin in ChEMBL Registered studies below
Show the 25 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clarithromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing

    NCT07533422 · start 2026-05-12

    Registered record
    Registry ID
    NCT07533422
    Conditions
    HELICOBACTER PYLORI INFECTIONS; Rescue Therapy for Helicobacter Pylori
    Interventions
    Personalized treatment based on the results of fecal antimicrobial resistance gene testing; Conventional Quadruple Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-12
    Completion
    2027-02-01
    Enrolment
    531

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS; Rescue Therapy for Helicobacter Pylori
    InterventionPersonalized treatment based on the results of fecal antimicrobial resistance gene testing; Conventional Quadruple Therapy
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Fecal Molecular Susceptibility-guided Hp First-line Therapy

    NCT07405684 · start 2026-02-28

    Registered record
    Registry ID
    NCT07405684
    Conditions
    HELICOBACTER PYLORI INFECTIONS
    Interventions
    7-day fecal molecular susceptibility-guided therapy; 14-day fecal molecular susceptibility-guided therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-02-28
    Completion
    2028-12-31
    Enrolment
    544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS
    Intervention7-day fecal molecular susceptibility-guided therapy; 14-day fecal molecular susceptibility-guided therapy
    PhasePhase 4
    Registry statusNot yet recruiting

  • Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin

    NCT07382661 · start 2026-02

    Registered record
    Registry ID
    NCT07382661
    Conditions
    Healthy Adult Volunteers
    Interventions
    DW4421; DW4421-1; DW4421-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-02
    Completion
    2026-10
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Volunteers
    InterventionDW4421; DW4421-1; DW4421-2
    PhasePhase 1
    Registry statusNot yet recruiting

  • Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication

    NCT06959368 · start 2025-03-25

    Registered record
    Registry ID
    NCT06959368
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-03-25
    Completion
    2026-03-25
    Enrolment
    484

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg
    PhasePhase 4
    Registry statusRecruiting

  • Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin

    NCT06551623 · start 2024-08-26

    Registered record
    Registry ID
    NCT06551623
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Midazolam; Clarithromycin; TNP-2198
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-08-26
    Completion
    2024-10-14
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionMidazolam; Clarithromycin; TNP-2198
    PhasePhase 1
    Registry statusCompleted

  • Effect of Pharmacokinetics in Healthy Chinese Subjects

    NCT06005714 · start 2023-08-15

    Registered record
    Registry ID
    NCT06005714
    Conditions
    The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects
    Interventions
    Mindeudesivir hydrobromide tablets and Clarithromycin tablets; Mindeudesivir hydrobromide tablets and Cyclosporine softgels
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-08-15
    Completion
    2023-10-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects
    InterventionMindeudesivir hydrobromide tablets and Clarithromycin tablets; Mindeudesivir hydrobromide tablets and Cyclosporine softgels
    PhasePhase 1
    Registry statusCompleted

  • Role of Vitamin D Supplementation as an Adjuvant Therapy inTreatment of Helicobacter Pylori in Children

    NCT05879237 · start 2023-06-01

    Registered record
    Registry ID
    NCT05879237
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vitamin D3; Helicobacter pylori triple therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-06-01
    Completion
    2023-12-10
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVitamin D3; Helicobacter pylori triple therapy
    PhaseNot applicable
    Registry statusUnknown

  • Effect of Probiotics on Gut Microbiota During the Helicobacter Pylori Eradication

    NCT05662514 · start 2023-02-15

    Registered record
    Registry ID
    NCT05662514
    Conditions
    Helicobacter Pylori Infection; Gut Microbiota
    Interventions
    Bifidobacterium animalis subsp. lactis BLa80; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-02-15
    Completion
    2024-01-15
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Gut Microbiota
    InterventionBifidobacterium animalis subsp. lactis BLa80; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile

    NCT05926804 · start 2022-08-02

    Registered record
    Registry ID
    NCT05926804
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Lansoprazole; Amoxicillin; Clarithromycin; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-08-02
    Completion
    2027-08
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionLansoprazole; Amoxicillin; Clarithromycin; Metronidazole
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection

    NCT05332444 · start 2022-04-11

    Registered record
    Registry ID
    NCT05332444
    Conditions
    Helicobacter Pylori Infection
    Interventions
    susceptibility-guided tailored therapy (Group A); guidelines-recommended empiric therapy (Group B)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-04-11
    Completion
    2026-12
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionsusceptibility-guided tailored therapy (Group A); guidelines-recommended empiric therapy (Group B)
    PhasePhase 4
    Registry statusRecruiting

  • Helicobacter Pylori Eradication and Follow-up

    NCT05061732 · start 2021-09-30

    Registered record
    Registry ID
    NCT05061732
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Rabeprazole; Bismuth potassium citrate; Metronidazole; Clarithromycin; Levofloxacin; Amoxicillin; Metronidazole; Doxycycline; Tetracycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-09-30
    Completion
    2026-06-30
    Enrolment
    4,447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionRabeprazole; Bismuth potassium citrate; Metronidazole; Clarithromycin +5 more
    PhasePhase 4
    Registry statusUnknown

  • Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children

    NCT05861687 · start 2021-08-01

    Registered record
    Registry ID
    NCT05861687
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Esomeprazole; Lansoprazole; Amoxicillin; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-08-01
    Completion
    2022-05-20
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionEsomeprazole; Lansoprazole; Amoxicillin; Clarithromycin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients

    NCT05417997 · start 2021-05-29

    Registered record
    Registry ID
    NCT05417997
    Conditions
    COVID-19 Respiratory Infection; FLU; Cold; Influenza; Bacterial Pneumonia; COVID-19 Pneumonia
    Interventions
    Kunamin®; Favipiravir; Enoxaparin; Lansoprazole; Paracetamol; Ceftriaxone/ Clarithromycin; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-05-29
    Completion
    2021-12-02
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Respiratory Infection; FLU; Cold; Influenza +2 more
    InterventionKunamin®; Favipiravir; Enoxaparin; Lansoprazole +3 more
    PhasePhase 3
    Registry statusCompleted

  • Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

    NCT05194046 · start 2020-11-18

    Registered record
    Registry ID
    NCT05194046
    Conditions
    Helicobacter Pylori Associated Gastrointestinal Disease
    Interventions
    JP-1366 20mg 1capsule; Amoxicillin 500Mg Cap; Clarithromycin 500Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-18
    Completion
    2021-01-19
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Associated Gastrointestinal Disease
    InterventionJP-1366 20mg 1capsule; Amoxicillin 500Mg Cap; Clarithromycin 500Mg Tab
    PhasePhase 1
    Registry statusCompleted

  • Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

    NCT04551963 · start 2020-11-15

    Registered record
    Registry ID
    NCT04551963
    Conditions
    B-cell Malignancies
    Interventions
    Zanubrutinib; Fluconazole; Diltiazem; Voriconazole; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-15
    Completion
    2022-02-21
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Malignancies
    InterventionZanubrutinib; Fluconazole; Diltiazem; Voriconazole +1 more
    PhasePhase 1
    Registry statusCompleted